Dr. Priya Chockalingam

Vice President, Head of Clinical BioAnalytics & Translational Sciences, Beam Therapeutics

The promise of single-cell multimodal analysis in cell and gene therapies

Dr. Priya Chockalingam discusses the transformative impact of cell and gene therapy development on the future of healthcare. She explores the challenges posed by the complexity of gene-edited products and sheds light on the potential of single-cell multi-modal analysis to enhance the success of these therapies. Plus, she shares her insights on how to address the challenges of cell and gene therapies to realize their full potential in curing diseases at the molecular level.

This video was filmed at AAPS 2023 PharmSci 360.

Want the latest expert interviews, articles, webinars, virtual summits and more direct to your inbox? Become a SelectScience member for free today>> 



LIKE 0
Dr. Priya Chockalingam
Health Sciences Precision Medicine

Dr. Priya Chockalingam

Biography

Dr. Priya Chockalingam holds... More
Follow Priya

Dr. Priya Chockalingam

Vice President, Head of Clinical BioAnalytics & Translational Sciences, Beam Therapeutics

Dr. Priya Chockalingam holds a Ph.D. in biochemistry and, with over 20 years of experience in translational medicine, bioanalytics, biomarkers, and diagnostics, she currently serves as the VP and Head of Clinical Bioanalytics & Translational Sciences at Beam Therapeutics. In this role, she oversees a team that collaborates across research and development, focusing on bioanalytical, biomarker, and translational strategies, with a strong emphasis on implementing these approaches for a diverse range of clinical programs. These programs encompass areas such as hematology, immunology, oncology, and rare genetic diseases, and involve cutting-edge technologies like base editing, auto/allo cell therapies, and innovative delivery methods like lipid nanoparticles (LNP).